PKIS v2.0 A clinical tool for identifying important pharmacokinetic drug-drug interactions

Footnotes and References

a.likely to be a major inhibitor based on subjective evaluation (≥ 2-fold AUC increase or ≥ 50% decrease in clearance of in vivo CYP probe).
Disclaimer
WARNING: While all efforts were put in to maintain the accuracy and currency of the information, it is possible that the knowledge and electronic tools may contain errors and inadequacy. Both Flinder's University and University of New South Wales are not liable to any damages or losses resulted from such circumstances. Clinical discretions are strongly advised at all times.